Destabilase — Dual-Function Thrombolytic & Antimicrobial Enzyme

• Molecular weight: ~12–13 kDa (varies by isoform; Ds-1 ~12.5 kDa, Ds-2 ~12.7 kDa)
• Classification: EC 3.4.—.— (isopeptidase) and EC 3.2.1.17 (muramidase / lysozyme)
• Gene family: Destabilase-lysozyme (i-lysozyme) superfamily
• Structure: Compact globular protein; partial crystal structure characterization indicates a fold distinct from classical c-type and g-type lysozymes, placing it in the invertebrate-type (i-type) lysozyme family
• Active sites: Two catalytic functions appear to be mediated by overlapping but non-identical active-site residues within the same structural domain
• Discovery: Baskova & Nikonov (1985); isopeptidase activity characterized in detail by 1991; muramidase activity confirmed through peptidoglycan hydrolysis assays

At least three destabilase isoforms have been characterized from Hirudo medicinalis, designated Ds-1, Ds-2, and Ds-3. These isoforms differ in molecular weight, tissue distribution, and relative catalytic activities:

The existence of multiple isoforms with different tissue distributions suggests that destabilase serves both localized (salivary/feeding) and systemic (immune defense) roles within the leech. Isoform-specific expression may also allow fine-tuning of isopeptidase versus muramidase activity ratios depending on physiological context.

The isopeptidase activity of destabilase targets a specific and unusual chemical bond: the ε(γ-Glu)-Lys isopeptide bond. This crosslink is formed by Factor XIIIa (fibrin-stabilizing factor, a transglutaminase) during the final step of the coagulation cascade, converting soluble fibrin into insoluble, mechanically stabilized fibrin clot.

Mechanism in Detail

1. Fibrin formation: Thrombin cleaves fibrinogen to fibrin monomers, which polymerize into a soft fibrin mesh.
2. Fibrin stabilization: Factor XIIIa catalyzes covalent ε(γ-Glu)-Lys isopeptide bonds between adjacent fibrin γ-chains and α-chains, creating a mechanically robust, insoluble clot.
3. Destabilase action: Destabilase hydrolyzes these isopeptide crosslinks directly, converting stabilized (crosslinked) fibrin back to soluble fragments — effectively “destabilizing” the clot (hence the name).

The ε(γ-Glu)-Lys isopeptide bond is not exclusive to fibrin — it also occurs in other transglutaminase-crosslinked proteins. However, destabilase shows preferential activity toward fibrin crosslinks, likely due to structural complementarity with the fibrin substrate.

The second catalytic function of destabilase is muramidase (N-acetylmuramidase) activity, biochemically equivalent to lysozyme. This activity was a major discovery because it demonstrated that a single enzyme can function simultaneously as a thrombolytic and an antimicrobial agent.

Substrate Specificity

Destabilase cleaves the β(1→4) glycosidic bond between N-acetylmuramic acid (MurNAc) and N-acetylglucosamine (GlcNAc) in bacterial peptidoglycan — the same bond targeted by hen egg-white lysozyme (HEWL). This specificity places destabilase functionally in the lysozyme family, although structurally it belongs to the invertebrate-type (i-type) lysozyme subfamily rather than the classical c-type.

Antimicrobial Spectrum

• Primary targets: Gram-positive bacteria, which have thick, exposed peptidoglycan layers (e.g., Staphylococcus, Bacillus, Micrococcus)
• Limited activity: Gram-negative bacteria have an outer membrane shielding the peptidoglycan layer, reducing direct access; however, synergy with other salivary compounds (e.g., complement inhibitors, membrane-disrupting peptides) may enable activity in vivo
• Biological role: Protects the leech crop from bacterial overgrowth during the prolonged blood digestion period — a single blood meal may be digested over 6–18 months, requiring sustained antimicrobial defense

Destabilase belongs to the invertebrate-type (i-type) lysozyme family, which is structurally distinct from the well-characterized c-type (chicken-type) and g-type (goose-type) lysozymes found in vertebrates. Key structural features include:

• Fold type: i-type lysozyme fold with partial structural characterization; the overall topology differs from the classical lysozyme fold despite conserved catalytic function
• Catalytic residues: Conserved glutamic acid and aspartic acid residues in the active site mediate the muramidase function, analogous to Glu35 and Asp52 in HEWL
• Bifunctional active site: The isopeptidase catalytic residues are situated in close spatial proximity to the muramidase active site but are not identical, allowing both activities to coexist
• Disulfide bonds: Multiple intramolecular disulfide bonds stabilize the compact structure, consistent with secretion into an oxidizing extracellular environment

Full high-resolution crystal structure determination remains an active area of research. Partial characterization has confirmed the i-type fold but complete atomic-resolution mapping of both catalytic sites has not yet been published.

To appreciate destabilase's unique pharmacological profile, it is instructive to compare it with established thrombolytic agents:

The key differentiator is that destabilase operates through a fundamentally different fibrinolytic pathway than all currently approved thrombolytics. While tPA and streptokinase both rely on converting plasminogen to plasmin (which then degrades fibrin), destabilase bypasses the plasminogen system entirely and directly cleaves the crosslinks that hold mature clots together. This suggests potential efficacy against plasmin-resistant, aged thrombi — a major unmet clinical need.

Recombinant destabilase (rDestabilase) has been successfully produced in several expression systems to enable research-scale production independent of leech harvesting:

• Escherichia coli: Bacterial expression produces inclusion bodies requiring refolding; yields active isopeptidase but muramidase activity may be reduced depending on refolding efficiency
• Yeast (Pichia pastoris): Eukaryotic expression system with proper folding and secretion; produces soluble, active enzyme with both catalytic functions preserved
• Insect cell systems: Baculovirus-mediated expression has been explored for high-fidelity post-translational modification

Recombinant production is essential for pharmaceutical development because native destabilase extraction from leech SGS yields extremely small quantities. The ability to produce rDestabilase at scale while preserving both catalytic activities is a prerequisite for any future clinical development pathway.

Destabilase has attracted sustained pharmaceutical interest due to its unique mechanism and dual functionality:

Destabilase is a cornerstone of the leech's blood-feeding adaptation, serving complementary roles that together solve the central challenge of hematophagy — maintaining a liquid, sterile blood meal for months of digestion:

1. Fibrinolysis during feeding: As the leech ingests blood, destabilase in the saliva immediately begins dissolving Factor XIIIa-crosslinked fibrin, preventing clot formation in the crop. This complements hirudin (which inhibits thrombin) — together they provide redundant anticoagulation through different mechanisms.
2. Long-term clot prevention: Blood stored in the crop for months would gradually crosslink and solidify without ongoing isopeptidase activity. Destabilase provides continuous fibrin dissolution during the entire digestion period.
3. Antimicrobial defense: The muramidase activity prevents bacterial overgrowth in the blood-filled crop. This is essential because the crop environment (warm, nutrient-rich, low oxygen) would otherwise be an ideal bacterial culture medium.
4. Coordination with the microbiome: The leech maintains a specialized gut microbiome dominated by Aeromonas (Gram-negative), which is naturally resistant to muramidase. Destabilase selectively eliminates Gram-positive competitors while the symbiotic Aeromonas assists with blood digestion.

• Baskova IP, Nikonov GI. Destabilase — an enzyme of medicinal leech SGSry gland secretion hydrolyzes isopeptide bonds in stabilized fibrin. Biokhimiya. 1985;50(3):424–431.
• Baskova IP, Zavalova LL. Proteinase inhibitors from the medicinal leech Hirudo medicinalis. Biochemistry (Moscow). 2001;66(7):703–714.
• Zavalova LL, Baskova IP, Lukyanov SA, et al. Destabilase from the medicinal leech is a representative of a novel family of lysozymes. Biochim Biophys Acta. 2000;1478(1):69–77.
• Kurdyumov AS, Manuvera VA, Baskova IP, Lazarev VN. A comparison of the enzymatic properties of three recombinant isoforms of thrombolytic and antibacterial protein — destabilase-lysozyme of medicinal leech. BMC Biochem. 2015;16:27.